Improving macroeconomic conditions and increased political certainty point to a favourable outlook for IPO activity across ...

In 2009, the outlook for Eli Lilly was uncertain. But a dogged commitment to R&D has shored up its future and positioned it at the forefront of pharma innovation. Pursuing organic growth is often ...

AI, automation and acquisitions are some of the key agenda items for respondents to our latest MT Asks. All the latest news, ...